Aymeric Duclert

Title: Aymeric Duclert: Innovator in Cellular Immunotherapy

Introduction

Aymeric Duclert is a prominent inventor based in Saint Maur des Fosses, France. He has made significant contributions to the field of immunotherapy, particularly in cancer treatment. With a total of 2 patents, Duclert is recognized for his innovative approaches to enhancing therapeutic efficacy.

Latest Patents

Duclert's latest patents include groundbreaking inventions that focus on cellular immunotherapy. The first patent, titled "Cellular immunotherapy for repetitive administration," provides composition kits and methods for treating cancer in humans through immunotherapy. This method utilizes successive doses of CAR-T cells, aiming to minimize or eliminate the anamnestic immune reaction in individuals. The second patent, "Use of endonucleases for inserting transgenes into safe harbor loci," involves endonucleases capable of cleaving target sequences located in safe harbor loci. This invention allows for the safe expression of transgenes by inserting them into cells, tissues, or individuals.

Career Highlights

Aymeric Duclert has established himself as a key figure in the biotechnology sector. He works at Cellectis, a company known for its pioneering work in gene editing and immunotherapy. His expertise and innovative mindset have positioned him as a leader in developing advanced therapeutic solutions.

Collaborations

Duclert collaborates with notable professionals in the field, including Olivier Danos and David Sourdive. These partnerships enhance the research and development efforts at Cellectis, driving forward the mission to improve cancer treatment through innovative technologies.

Conclusion

Aymeric Duclert's contributions to cellular immunotherapy and gene editing exemplify the impact of innovation in medicine. His patents reflect a commitment to advancing cancer treatment, showcasing the potential of immunotherapy in improving patient outcomes.